InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Browse the complete record of transactions filed by Flynn Karen, Président des Biologiques et CCO. Director active across 2 companies, notably Catalent, Inc.. Cumulatively, 5 reports have been published. Total volume traded: €508k. The latest transaction was disclosed on 6 June 2022 — Attribution. Regulator: SEC (Form 4). The full history is openly available.
Declarations5 total
013,227 shares0
Common Stock
SEC:0001562180-22-005091:0·
€253,9502,472 shares@ €102.730750.0% of flow
Common Stock
SEC:0001596783-22-000014:0·
€253,9502,472 shares@ €102.7307100.0% of flow
Common Stock
SEC:0001596783-22-000014·
01,151 shares0
Common Stock
SEC:0001596783-21-000092·
01,151 shares0
Common Stock
SEC:0001596783-21-000092:0·
5 of 5 declarations
About Flynn Karen
Karen Flynn is the President of Biologics and CCO at Catalent, Inc. and Quanterix Corp. She oversees the company's commercial and strategic operations. Her role is crucial in ensuring growth and innovation in the biopharmaceutical sector.
